title: Levetiracetam.
abstract: [Symbol: see text] Levetiracetam is an ethyl analogue of the nootropic agent piracetam.[Symbol: see text] Results from rodent studies indicate that the drug may offer protection against absence, generalised and partial seizures.[Symbol: see text] Levetiracetam exhibits linear pharmacokinetics and has a wide therapeutic index. Its potential to interact with other anticonvulsants appears to be low.[Symbol: see text] Initial findings from a total of 29 patients with treatment-refractory epilepsy suggest that levetiracetam may be beneficial in patients with partial seizures. These results require confirmation.[Symbol: see text] Somnolence and asthenia were the most common adverse events reported in patients receiving levetiracetam 1000 to 4000 mg/day; these appeared to be dose-related.
authors: Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand, demail@adis.co.nz.
authors: M
authors: M
authors: Haria
authors: J A
authors: JA
authors: Balfour